|
Gene: CHMP1B |
Gene summary for CHMP1B |
Gene summary. |
Gene information | Species | Human | Gene symbol | CHMP1B | Gene ID | 57132 |
Gene name | charged multivesicular body protein 1B | |
Gene Alias | C10orf2 | |
Cytomap | 18p11.21 | |
Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q7LBR1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57132 | CHMP1B | CCI_1 | Human | Cervix | CC | 1.94e-05 | -5.13e-01 | 0.528 |
57132 | CHMP1B | CCI_2 | Human | Cervix | CC | 7.14e-05 | -5.13e-01 | 0.5249 |
57132 | CHMP1B | CCI_3 | Human | Cervix | CC | 1.02e-07 | -5.13e-01 | 0.516 |
57132 | CHMP1B | CCII_1 | Human | Cervix | CC | 3.27e-11 | -5.13e-01 | 0.3249 |
57132 | CHMP1B | sample3 | Human | Cervix | CC | 6.56e-06 | -1.39e-01 | 0.1387 |
57132 | CHMP1B | T3 | Human | Cervix | CC | 8.96e-06 | -1.48e-01 | 0.1389 |
57132 | CHMP1B | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.70e-09 | 2.41e-01 | -0.1808 |
57132 | CHMP1B | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.43e-08 | 3.09e-01 | -0.0811 |
57132 | CHMP1B | HTA11_78_2000001011 | Human | Colorectum | AD | 2.48e-07 | 2.13e-01 | -0.1088 |
57132 | CHMP1B | HTA11_347_2000001011 | Human | Colorectum | AD | 1.02e-14 | 3.16e-01 | -0.1954 |
57132 | CHMP1B | HTA11_411_2000001011 | Human | Colorectum | SER | 1.20e-07 | 4.72e-01 | -0.2602 |
57132 | CHMP1B | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.26e-04 | 1.69e-01 | -0.1207 |
57132 | CHMP1B | HTA11_696_2000001011 | Human | Colorectum | AD | 7.82e-13 | 2.36e-01 | -0.1464 |
57132 | CHMP1B | HTA11_866_2000001011 | Human | Colorectum | AD | 9.04e-05 | 1.23e-01 | -0.1001 |
57132 | CHMP1B | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.21e-08 | 2.25e-01 | -0.059 |
57132 | CHMP1B | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.51e-04 | 2.63e-01 | -0.1706 |
57132 | CHMP1B | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.28e-02 | 1.70e-01 | -0.2061 |
57132 | CHMP1B | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.24e-02 | 1.79e-01 | -0.0179 |
57132 | CHMP1B | HTA11_866_3004761011 | Human | Colorectum | AD | 5.92e-06 | 1.66e-01 | 0.096 |
57132 | CHMP1B | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.58e-06 | 3.83e-01 | 0.0131 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00619526 | Skin | cSCC | midbody abscission | 15/4864 | 17/18723 | 1.27e-07 | 2.93e-06 | 15 |
GO:00190688 | Skin | cSCC | virion assembly | 24/4864 | 35/18723 | 1.56e-07 | 3.51e-06 | 24 |
GO:00325098 | Skin | cSCC | endosome transport via multivesicular body sorting pathway | 22/4864 | 31/18723 | 2.00e-07 | 4.34e-06 | 22 |
GO:00397028 | Skin | cSCC | viral budding via host ESCRT complex | 17/4864 | 21/18723 | 2.14e-07 | 4.60e-06 | 17 |
GO:00069976 | Skin | cSCC | nucleus organization | 62/4864 | 133/18723 | 2.21e-07 | 4.72e-06 | 62 |
GO:00467557 | Skin | cSCC | viral budding | 19/4864 | 26/18723 | 6.73e-07 | 1.26e-05 | 19 |
GO:000703215 | Skin | cSCC | endosome organization | 42/4864 | 82/18723 | 8.86e-07 | 1.63e-05 | 42 |
GO:006023615 | Skin | cSCC | regulation of mitotic spindle organization | 23/4864 | 35/18723 | 9.13e-07 | 1.66e-05 | 23 |
GO:00453246 | Skin | cSCC | late endosome to vacuole transport | 18/4864 | 25/18723 | 1.91e-06 | 3.17e-05 | 18 |
GO:009022414 | Skin | cSCC | regulation of spindle organization | 24/4864 | 39/18723 | 3.02e-06 | 4.72e-05 | 24 |
GO:00719857 | Skin | cSCC | multivesicular body sorting pathway | 23/4864 | 37/18723 | 3.80e-06 | 5.70e-05 | 23 |
GO:009016915 | Skin | cSCC | regulation of spindle assembly | 17/4864 | 25/18723 | 1.27e-05 | 1.60e-04 | 17 |
GO:007050716 | Skin | cSCC | regulation of microtubule cytoskeleton organization | 61/4864 | 148/18723 | 3.61e-05 | 3.90e-04 | 61 |
GO:19048966 | Skin | cSCC | ESCRT complex disassembly | 9/4864 | 10/18723 | 4.11e-05 | 4.34e-04 | 9 |
GO:19049036 | Skin | cSCC | ESCRT III complex disassembly | 9/4864 | 10/18723 | 4.11e-05 | 4.34e-04 | 9 |
GO:190167317 | Skin | cSCC | regulation of mitotic spindle assembly | 13/4864 | 18/18723 | 5.27e-05 | 5.35e-04 | 13 |
GO:190211515 | Skin | cSCC | regulation of organelle assembly | 72/4864 | 186/18723 | 8.90e-05 | 8.35e-04 | 72 |
GO:00310234 | Skin | cSCC | microtubule organizing center organization | 58/4864 | 143/18723 | 9.47e-05 | 8.83e-04 | 58 |
GO:00070983 | Skin | cSCC | centrosome cycle | 53/4864 | 130/18723 | 1.59e-04 | 1.39e-03 | 53 |
GO:003288612 | Skin | cSCC | regulation of microtubule-based process | 82/4864 | 240/18723 | 2.82e-03 | 1.58e-02 | 82 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHMP1B | SNV | Missense_Mutation | novel | c.481N>T | p.Gly161Cys | p.G161C | Q7LBR1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CHMP1B | SNV | Missense_Mutation | novel | c.107N>A | p.Ile36Asn | p.I36N | Q7LBR1 | protein_coding | deleterious(0) | benign(0.361) | TCGA-BH-AB28-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
CHMP1B | insertion | In_Frame_Ins | novel | c.482_483insTAT | p.Gly161_Leu162insIle | p.G161_L162insI | Q7LBR1 | protein_coding | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
CHMP1B | SNV | Missense_Mutation | c.94N>A | p.Glu32Lys | p.E32K | Q7LBR1 | protein_coding | deleterious(0.02) | possibly_damaging(0.903) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
CHMP1B | insertion | Frame_Shift_Ins | rs756274240 | c.72dupA | p.Cys25MetfsTer3 | p.C25Mfs*3 | Q7LBR1 | protein_coding | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CHMP1B | SNV | Missense_Mutation | novel | c.195N>A | p.Phe65Leu | p.F65L | Q7LBR1 | protein_coding | tolerated(1) | possibly_damaging(0.506) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CHMP1B | SNV | Missense_Mutation | novel | c.289A>G | p.Lys97Glu | p.K97E | Q7LBR1 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CHMP1B | SNV | Missense_Mutation | novel | c.214N>C | p.Val72Leu | p.V72L | Q7LBR1 | protein_coding | tolerated(0.28) | benign(0.007) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHMP1B | SNV | Missense_Mutation | c.256N>T | p.Gly86Cys | p.G86C | Q7LBR1 | protein_coding | deleterious(0) | possibly_damaging(0.762) | TCGA-BS-A0UL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CHMP1B | SNV | Missense_Mutation | novel | c.195N>A | p.Phe65Leu | p.F65L | Q7LBR1 | protein_coding | tolerated(1) | possibly_damaging(0.506) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |